HealthyWay Inc. has provided a further update regarding the disposal of its equity interest in a subsidiary. The company confirmed that the consideration for the sale was determined through arm's length negotiations, referencing an independent valuation of 100% equity interest in the subsidiary at RMB3.29 million as of 31 October 2025. The valuation was based on the income approach, and KPMG was engaged to verify the accuracy of the discounted future cash flow calculations used in the assessment. The board confirmed that the profit forecast in the valuation report was made after due and careful enquiry.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HealthyWay Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260119-11995104), on January 19, 2026, and is solely responsible for the information contained therein.
Comments